Clinical Trial Detail

NCT ID NCT03537482
Title APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ascentage Pharma Group Inc.
Indications

non-Hodgkin lymphoma

acute myeloid leukemia

chronic lymphocytic leukemia

multiple myeloma

diffuse large B-cell lymphoma

lymphoplasmacytic lymphoma

mantle cell lymphoma

Therapies

APG-2575

Age Groups: senior adult

No variant requirements are available.